Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 19, 2024 9:48am

62 Views

Post# 36185694

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

Additionally Stewart et.al. (2019) found that "topoisomerase inhibitors are a class of drugs that enhance reovirus infectivity and cytotoxicity of triple-negative breast cancer cells."

Dato-DXd is a TROP-2-directed ADC where a humanized anti-TROP-2 IgG1 MAb is attached to a topoisomerase I inhibitor payload via tetrapeptide-based cleavable linker.

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project